[{"id":"0db89e9b-db2b-43cc-83d7-77deb9d111cd","acronym":"SCOUT","url":"https://clinicaltrials.gov/study/NCT02637687","created_at":"2021-01-17T17:20:37.992Z","updated_at":"2025-02-25T12:26:24.234Z","phase":"Phase 1/2","brief_title":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","source_id_and_acronym":"NCT02637687 - SCOUT","lead_sponsor":"Bayer","biomarkers":" NTRK3 • ETV6 • NTRK","pipe":" | ","alterations":" NTRK positive • NTRK fusion","tags":["NTRK3 • ETV6 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Vitrakvi (larotrectinib) • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 12/16/2015","start_date":" 12/16/2015","primary_txt":" Primary completion: 07/20/2024","primary_completion_date":" 07/20/2024","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-24"},{"id":"722e7e39-2b2e-4e81-be40-58b1e321be96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043713","created_at":"2023-09-21T15:10:30.740Z","updated_at":"2025-02-25T13:41:44.027Z","phase":"Phase 1","brief_title":"Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations","source_id_and_acronym":"NCT06043713","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK","pipe":" | ","alterations":" KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion","tags":["HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 12/15/2023","start_date":" 12/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 02/09/2026","study_completion_date":" 02/09/2026","last_update_posted":"2025-02-21"},{"id":"204cae00-5d2c-422e-af6c-ba51e68ea377","acronym":"CONNECT1903","url":"https://clinicaltrials.gov/study/NCT04655404","created_at":"2021-01-19T20:41:28.986Z","updated_at":"2025-02-25T14:15:44.274Z","phase":"Phase 1","brief_title":"A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma with NTRK Fusion","source_id_and_acronym":"NCT04655404 - CONNECT1903","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-18"},{"id":"a1cc20b7-e120-4c96-ad2e-1583010cd20c","acronym":"CARE study","url":"https://clinicaltrials.gov/study/NCT04094610","created_at":"2021-01-18T20:02:04.781Z","updated_at":"2025-02-25T14:40:19.057Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","source_id_and_acronym":"NCT04094610 - CARE study","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/12/2020","start_date":" 03/12/2020","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-14"},{"id":"f02c2f2b-a093-410f-90e0-01cc532b5f16","acronym":"","url":"https://clinicaltrials.gov/study/NCT04786093","created_at":"2021-03-08T12:53:40.787Z","updated_at":"2025-02-25T15:11:58.304Z","phase":"Phase 2","brief_title":"Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC","source_id_and_acronym":"NCT04786093","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" PD-L1 • BRAF • ALK • ROS1 • PD-1 • CTLA4 • NTRK","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • ALK rearrangement • ROS1 fusion • NTRK fusion","tags":["PD-L1 • BRAF • ALK • ROS1 • PD-1 • CTLA4 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • ALK rearrangement • ROS1 fusion • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 07/27/2021","start_date":" 07/27/2021","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-13"},{"id":"393ae514-083b-4a6f-a6c0-c472fe56deef","acronym":"KEYNOTE-E59","url":"https://clinicaltrials.gov/study/NCT05083481","created_at":"2021-10-19T15:58:03.788Z","updated_at":"2025-02-25T15:19:18.701Z","phase":"Phase 1/2","brief_title":"A Study of ASP1570 Alone or in Combination With Pembrolizumab or Standard Therapies in Adults With Solid Tumors","source_id_and_acronym":"NCT05083481 - KEYNOTE-E59","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • NTRK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ALK positive • ALK mutation • NTRK fusion","tags":["EGFR • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ALK positive • ALK mutation • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • docetaxel • Lonsurf (trifluridine/tipiracil) • ASP1570"],"overall_status":"Recruiting","enrollment":" Enrollment 310","initiation":"Initiation: 10/19/2021","start_date":" 10/19/2021","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-12"},{"id":"c0529000-1eea-42c3-9cae-d983a7189b6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05943795","created_at":"2023-07-13T18:10:45.267Z","updated_at":"2025-02-25T15:36:23.229Z","phase":"Phase 3","brief_title":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","source_id_and_acronym":"NCT05943795","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • izalontamab (SI-B001)"],"overall_status":"Recruiting","enrollment":" Enrollment 584","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-11"},{"id":"1c1d3f40-f2af-499a-b04e-123bc4d694d0","acronym":"ON-TRK","url":"https://clinicaltrials.gov/study/NCT04142437","created_at":"2021-01-18T20:13:13.808Z","updated_at":"2025-02-25T15:26:13.445Z","phase":"","brief_title":"Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body","source_id_and_acronym":"NCT04142437 - ON-TRK","lead_sponsor":"Bayer","biomarkers":" NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/03/2020","start_date":" 04/03/2020","primary_txt":" Primary completion: 11/30/2029","primary_completion_date":" 11/30/2029","study_txt":" Completion: 03/31/2030","study_completion_date":" 03/31/2030","last_update_posted":"2025-02-10"},{"id":"a960e964-3a5f-401a-844c-ae8dd61b3da6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213704","created_at":"2023-12-06T19:15:43.766Z","updated_at":"2025-02-25T16:51:56.748Z","phase":"Phase 2","brief_title":"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213704","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 08/23/2017","start_date":" 08/23/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 10/08/2025","study_completion_date":" 10/08/2025","last_update_posted":"2025-02-04"},{"id":"9019c921-3c37-404e-9dcf-6b18ca280688","acronym":"EPI VITRAKVI","url":"https://clinicaltrials.gov/study/NCT05236257","created_at":"2022-02-11T12:52:54.392Z","updated_at":"2025-02-25T17:12:08.743Z","phase":"","brief_title":"A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database","source_id_and_acronym":"NCT05236257 - EPI VITRAKVI","lead_sponsor":"Bayer","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 09/13/2022","primary_completion_date":" 09/13/2022","study_txt":" Completion: 09/13/2022","study_completion_date":" 09/13/2022","last_update_posted":"2024-12-10"},{"id":"2b6e1463-c371-4b17-a2c1-81d56ff0988e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03215511","created_at":"2021-01-18T15:52:01.409Z","updated_at":"2025-02-25T17:09:49.126Z","phase":"Phase 1","brief_title":"A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer","source_id_and_acronym":"NCT03215511","lead_sponsor":"Bayer","biomarkers":" NTRK3 • ETV6 • NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK3 • ETV6 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e selitrectinib (BAY 2731954)"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 07/03/2017","start_date":" 07/03/2017","primary_txt":" Primary completion: 04/11/2022","primary_completion_date":" 04/11/2022","study_txt":" Completion: 01/30/2023","study_completion_date":" 01/30/2023","last_update_posted":"2024-10-30"},{"id":"f1eb15be-99b0-4993-89d8-1f3e74e59506","acronym":"","url":"https://clinicaltrials.gov/study/NCT05297903","created_at":"2022-03-28T13:52:59.235Z","updated_at":"2024-07-02T16:35:05.357Z","phase":"Phase 2","brief_title":"XmAb20717 in Advanced Biliary Tract Cancers","source_id_and_acronym":"NCT05297903","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" FGFR2 • IDH1 • NTRK","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion","tags":["FGFR2 • IDH1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-07"},{"id":"7bef29a7-07ed-4332-9706-9ee664c0f131","acronym":"Lung-MAP Non-Match Sub-Study","url":"https://clinicaltrials.gov/study/NCT05096663","created_at":"2021-10-27T14:53:21.327Z","updated_at":"2024-07-02T16:35:05.962Z","phase":"Phase 2/3","brief_title":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT05096663 - Lung-MAP Non-Match Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" BRAF mutation • ALK fusion • ROS1 fusion • MET mutation • NTRK fusion","tags":["EGFR • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • ALK fusion • ROS1 fusion • MET mutation • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln) • Hemady (dexamethasone tablets) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 03/15/2022","start_date":" 03/15/2022","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-05-03"},{"id":"e3283371-d5d3-4a68-bf39-709bf00315cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05701787","created_at":"2023-01-27T16:00:02.113Z","updated_at":"2024-07-02T16:35:09.119Z","phase":"","brief_title":"Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations","source_id_and_acronym":"NCT05701787","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" EGFR • KRAS • BRAF • ALK • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • RET fusion • ALK fusion • ROS1 fusion • KRAS G12 • ALK-ROS1 fusion • NTRK fusion","tags":["EGFR • KRAS • BRAF • ALK • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • RET fusion • ALK fusion • ROS1 fusion • KRAS G12 • ALK-ROS1 fusion • NTRK fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2024-04-17"},{"id":"3e8a5464-1824-497b-a119-17a66b58d38e","acronym":"NTRK","url":"https://clinicaltrials.gov/study/NCT05796258","created_at":"2023-04-03T14:03:08.055Z","updated_at":"2024-07-02T16:35:10.466Z","phase":"","brief_title":"Three-pronged Centralized Molecular Analysis to Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer","source_id_and_acronym":"NCT05796258 - NTRK","lead_sponsor":"Regina Elena Cancer Institute","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-10"},{"id":"fb17d34e-7575-4ea4-b3d4-30e9fd5c4402","acronym":"REALTRK","url":"https://clinicaltrials.gov/study/NCT04557813","created_at":"2021-01-18T21:47:07.063Z","updated_at":"2024-07-02T16:35:16.761Z","phase":"","brief_title":"Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion","source_id_and_acronym":"NCT04557813 - REALTRK","lead_sponsor":"iOMEDICO AG","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 12/02/2020","start_date":" 12/02/2020","primary_txt":" Primary completion: 10/25/2026","primary_completion_date":" 10/25/2026","study_txt":" Completion: 10/25/2026","study_completion_date":" 10/25/2026","last_update_posted":"2024-03-01"},{"id":"b7222b36-4294-4a60-9a60-79c17a69cc40","acronym":"MEKiAUTO","url":"https://clinicaltrials.gov/study/NCT04214418","created_at":"2021-01-18T20:31:18.521Z","updated_at":"2024-07-02T16:35:17.433Z","phase":"Phase 1/2","brief_title":"Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies","source_id_and_acronym":"NCT04214418 - MEKiAUTO","lead_sponsor":"Columbia University","biomarkers":" KRAS • MSI • NTRK","pipe":" | ","alterations":" KRAS mutation • MSI-H/dMMR • NTRK positive • NTRK fusion","tags":["KRAS • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • MSI-H/dMMR • NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib) • hydroxychloroquine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 175","initiation":"Initiation: 02/12/2020","start_date":" 02/12/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-02-28"},{"id":"416184c7-fe64-4ecf-8814-619fc7961341","acronym":"GAIN/iCat2","url":"https://clinicaltrials.gov/study/NCT02520713","created_at":"2021-02-22T08:55:49.474Z","updated_at":"2024-07-02T16:35:22.564Z","phase":"","brief_title":"The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study","source_id_and_acronym":"NCT02520713 - GAIN/iCat2","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" NTRK","pipe":" | ","alterations":" ALK fusion • NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • NTRK fusion"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 825","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-01-23"},{"id":"652c5256-d9cf-4341-a41c-dd696f4d2fa3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05024929","created_at":"2021-08-27T12:53:01.955Z","updated_at":"2024-07-02T16:35:23.047Z","phase":"","brief_title":"Targeted Therapy to Increase RAI Uptake in Metastatic DTC","source_id_and_acronym":"NCT05024929","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" BRAF • ALK • RET • NTRK","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • RET fusion • ALK fusion • ALK mutation • BRAF fusion • NTRK fusion","tags":["BRAF • ALK • RET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • RET fusion • ALK fusion • ALK mutation • BRAF fusion • NTRK fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/16/2021","start_date":" 07/16/2021","primary_txt":" Primary completion: 02/01/2031","primary_completion_date":" 02/01/2031","study_txt":" Completion: 02/01/2033","study_completion_date":" 02/01/2033","last_update_posted":"2024-01-18"},{"id":"11e80090-69af-4a10-8567-99e826b98c88","acronym":"","url":"https://clinicaltrials.gov/study/NCT05949606","created_at":"2023-07-20T15:09:17.002Z","updated_at":"2024-07-02T16:35:27.645Z","phase":"Phase 1/2","brief_title":"A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05949606","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • KRAS • BRAF • ALK • MET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • EGFR wild-type • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion","tags":["HER-2 • KRAS • BRAF • ALK • MET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • EGFR wild-type • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab (SI-B001) • danvilostomig (SI-B003)"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-11-29"},{"id":"0d144f9c-62b7-4fec-8e14-e3271c7c60fe","acronym":"LOXO-TRK-14001","url":"https://clinicaltrials.gov/study/NCT02122913","created_at":"2021-01-17T17:11:46.373Z","updated_at":"2025-02-25T17:07:27.905Z","phase":"Phase 1","brief_title":"A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer","source_id_and_acronym":"NCT02122913 - LOXO-TRK-14001","lead_sponsor":"Bayer","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Completed","enrollment":" Enrollment 75","initiation":"Initiation: 05/04/2014","start_date":" 05/04/2014","primary_txt":" Primary completion: 02/01/2017","primary_completion_date":" 02/01/2017","study_txt":" Completion: 04/09/2021","study_completion_date":" 04/09/2021","last_update_posted":"2023-11-06"},{"id":"27251627-9d01-4563-9673-f9cf20febcad","acronym":"","url":"https://clinicaltrials.gov/study/NCT05793281","created_at":"2023-03-31T15:02:54.101Z","updated_at":"2025-02-25T17:12:29.001Z","phase":"","brief_title":"An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan","source_id_and_acronym":"NCT05793281","lead_sponsor":"Bayer","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK positive • NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK positive • NTRK fusion"],"overall_status":"Completed","enrollment":" Enrollment 46621","initiation":"Initiation: 03/10/2023","start_date":" 03/10/2023","primary_txt":" Primary completion: 09/28/2023","primary_completion_date":" 09/28/2023","study_txt":" Completion: 09/28/2023","study_completion_date":" 09/28/2023","last_update_posted":"2023-10-25"},{"id":"8aea6752-9081-4156-8036-1fa904135caa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05935774","created_at":"2023-07-07T14:09:36.968Z","updated_at":"2024-07-02T16:35:38.985Z","phase":"Phase 2","brief_title":"OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05935774","lead_sponsor":"University of Washington","biomarkers":" HER-2 • BRAF • ALK • RET • ROS1 • CD4 • NTRK","pipe":" | ","alterations":" BRAF mutation • HER-2 mutation • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion","tags":["HER-2 • BRAF • ALK • RET • ROS1 • CD4 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HER-2 mutation • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • trabedersen (OT-101)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 07/31/2028","primary_completion_date":" 07/31/2028","study_txt":" Completion: 07/31/2028","study_completion_date":" 07/31/2028","last_update_posted":"2023-08-25"},{"id":"6575bade-72bb-495f-8e06-eb39a449767d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01639508","created_at":"2021-01-17T17:26:36.480Z","updated_at":"2024-07-02T16:35:44.723Z","phase":"Phase 2","brief_title":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity","source_id_and_acronym":"NCT01639508","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" RET • ROS1 • KIF5B • AXL • NTRK","pipe":" | ","alterations":" RET fusion • MET overexpression • KIF5B-RET fusion • ROS1 fusion • AXL overexpression • NTRK fusion","tags":["RET • ROS1 • KIF5B • AXL • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • MET overexpression • KIF5B-RET fusion • ROS1 fusion • AXL overexpression • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-06-26"}]